Home Recalls D-0436-2021
Class II · Moderate risk Terminated Initiated Mar 15, 2021 (5 years ago)
xigduo XR (dapagliflozin/metformin HCl extended-release) tablets 5 mg/1000 mg 60 Tablets…
Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.
Why it was recalled
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
What was recalled
xigduo XR (dapagliflozin/metformin HCl extended-release) tablets 5 mg/1000 mg 60 Tablets Rx only NDC 0310-6260-60 Manufactured for: AstraZeneca Pharmaceuticals LP Wilmington, DE 19850
Recalling firm Cardinal Health Inc.
NDC code 0310-6260-60
Origin OH, United States
Initiated by Voluntary: Firm initiated
FDA recall number D-0436-2021
What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.
Class II · Moderate risk Ongoing Jun 12, 2026
Reason CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been…
Class II · Moderate risk Ongoing Mar 13, 2025
Reason CGMP Deviations
Class II · Moderate risk Ongoing Feb 25, 2025
Reason Presence of Foreign Tablets/Capsules.
Class II · Moderate risk Terminated Dec 30, 2024
Reason Presence of Foreign Tablets/Capsules: A Paracetamol 500 mg tablet was found in a 1000-count bottle of Metformin HCL ER Tablets USP, 500 mg.
Class II · Moderate risk Terminated Feb 22, 2023
Reason CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.